替格瑞洛治疗急性冠脉综合征患者的临床安全性研究

Clinical Safety Study of Ticagrelor in the Treatment of Patients with Acute Coronary Syndrome

目的探究分析替格瑞洛治疗急性冠脉综合征患者的临床安全性。方法随机选择2019年8月—2021年9月期间在中煤矿建总医院治疗的ACS患者110例为研究对象,分为对照组和观察组,各55例。对照组使用氯吡格雷进行治疗,观察组使用替格瑞洛进行治疗,对比两组患者的临床疗效、心血管事件发生率、生活质量、不良反应。结果观察组治疗成效(94.55%)优于对照组(72.73%),差异有统计学意义(χ^(2)=9.565,P<0.05);观察组心血管事件的发生概率(3.64%)要明显低于对照组(21.82%),差异有统计学意义(χ^(2)=8.184,P<0.05)。治疗后,观察组生理功能、情感职能、社会功能以及精神健康指标数值均明显高于对照组,差异有统计学意义(t=7.672、6.703、10.629、7.606,P<0.05)。观察组不良反应发生率(5.45%)低于对照组(20.00%),差异有统计学意义(χ^(2)=5.238,P<0.05)。结论针对于患有急性冠脉综合征的患者,使用替格瑞洛进行疾病的医治,能够让患者获得与临床理想治疗效果相近的成效,患者在使用药物的过程中拥有较高的安全性,发生并发症的事件有所降低,患者的心血管状况与正常状态相接近,能够让患者的预后效果更加优良。

Objective To explore and analyze the clinical safety of ticagrelor in the treatment of patients with acute coronary syndrome.Methods 110 acute coronary syndrome patients who were treated in China Coal Mining General Hospital from August 2019 to September 2021 were randomly selected as the study subjects,and were divided into control group and observation group,with 55 patients in each group.The control group was treated with clopidogrel,while the observation group was treated with ticagrelor.The clinical efficacy,incidence rate of cardiovascular events,quality of life,and adverse reactions between two groups of patients was compared.Results The clinical efficacy of the observation group(94.55%)was better than that of the control group(72.73%),the difference was statistically signifi⁃cant(χ^(2)=9.565,P<0.05).The incidence rate of cardiovascular events in the observation group was 3.64%,which was lower than that in the control group(21.82%),the difference was statistically significant(χ^(2)=8.184,P<0.05).After treatment,the values of physiological function,emotional function,social function and mental health indicators in the observation group were higher than those in the control group,the difference was statistically significant(t=7.672,6.703,10.629,7.606,P<0.05).The incidence of adverse reactions in the observation group(5.45%)was lower than that in the control group(20.00%),and the difference was statistically significant(χ^(2)=5.238,P<0.05).Conclusion For patients with acute coronary syndrome,the use of ticagrelor for the treatment of the disease can enable patients to ob⁃tain an effect similar to the clinical ideal treatment effect.Patients have higher safety in the process of using drugs,the incidence of complications is reduced,and the cardiovascular status of patients is close to the normal state,which can make the prognosis of patients better.